[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Las Palmas de Gran Canaria\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":161},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,68,90,111,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100504870","non-invasive-neuromodulation-nesa-application-in-the-rehabilitation-of-stroke-sequelae-100504870",false,"NCT05853952","Non-invasive Neuromodulation NESA Application in the Rehabilitation of Stroke Sequelae","Non-invasive Neuromodulation NESA Application in the Rehabilitation of Stroke Sequelae. A Pilot Study","Inclusion Criteria:\n\n* People who have suffered a stroke with an evolution between 6 months and 6 years.\n* Optimal cognitive capacity and mentally competent to participate in the study and complete the required questionnaires.\n* People able of standing upright, including those who need technical aids.\n\nExclusion Criteria:\n\n* Present some of the contraindications for a treatment with NESA XSIGNAL®: pacemakers, internal bleeding, not to apply electrodes on skin in bad condition, with ulcerations or wounds, acute febrile processes, acute thrombophlebitis and\u002For phobia to electricity.\n* Not having signed the informed consent form.\n* Presenting any additional injury or pathology during the study.\n* Not having the optimal cognitive capacities for understanding and participating in the study.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","To evaluate whether NESA microcurrents can be used as an effective treatment for various sequelae present in stroke patients, specifically in the treatment of spasticity, balance, pain; and whether it affects quality of life, performance of activities of daily living and quality of sleep.",[26],"Stroke",[28,29],"physical therapy modality","Electric Stimulation Therapy","RECRUITING","2026-05-02",{"date":33,"type":34},"2026-05-05","ACTUAL",{"date":36,"type":34},"2023-04-24",{"date":38,"type":20},"2026-10-23",{"name":40,"class":41},"University of Las Palmas de Gran Canaria","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100456830","prevalence-of-long-covid-19-in-the-canary-islands-100456830","NCT05228691","Prevalence of Long COVID-19 in the Canary Islands","Long COVID: Evaluation of Physical and Functional Status","Inclusion Criteria:\n\n* Have been positive for COVID-19 since the declaration of the state of alarm throughout the Spanish territory to deal with the health emergency situation caused by COVID-19 (March 14, 2020).\n* Symptoms associated with COVID-19 at least after 12 weeks of its detection.\n* Adequate cognitive and physical level to understand and perform the tests evaluation.\n\nExclusion Criteria:\n\n* Present comorbidities prior to suffering from COVID-19 whose symptoms are resemble Post-acute COVID-19.\n* Fibromyalgia.\n* Chronic fatigue.\n* Neuromuscular disease.\n* Not having signed the informed consent.\n* Person undergoing treatment for active cancer.",{"count":51,"type":20},600,"6 Months","OBSERVATIONAL","With more than 246 million people diagnosed with coronavirus 2019 (COVID-19) around the world, many of whom have required medical attention for past 23 months, greater emphasis is being placed on post-acute care of COVID-19 survivors. According to recent data, millions of patients who have recovered from acute COVID-19 are experiencing persistent symptoms, which lead to disability and impaired activities of daily living.\n\nVarious terms have been used to describe the condition of patients who do not return to their initial health status to include post-acute sequelae of COVID-19, such as post-acute COVID syndrome (PACS) and Long COVID.\n\nThe growing global burden of COVID-19 suggests that the potential effects of Long COVID in public health are vast even if Long COVID is experienced by a small proportion of patients recovering from acute infection.\n\nThe ability to identify patients at high risk for Long COVID and forecasting medical resource requirements is of important clinical utility in the present.\n\nIn view of the large number of people surviving after infection with COVID-19 and that should require follow-up, determine which patients are at risk of have Long COVID and who require close monitoring is crucial. In this study, therefore, we set out to analyze what type of patient profile with COVID-19 who, after 12 weeks of having suffered the infection, experiences the signs and symptoms described by current literature.",[56],"COVID-19",[28,58,59],"Long COVID","post-acute COVID-19 syndrome","2025-08-21",{"date":62,"type":34},"2025-08-28",{"date":64,"type":34},"2022-03-22",{"date":66,"type":20},"2026-05-01",{"name":40,"class":41},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":42},"100455238","efficacy-of-the-nxsignal-device-for-the-treatment-of-anterior-cruciate-ligament-injuries-100455238","NCT05207943","Efficacy of the NXSignal Device for the Treatment of Anterior Cruciate Ligament Injuries","Efficacy of the NXSignal Device for the Treatment of Anterior Cruciate Ligament Injuries. Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Over 16 years old\n* In normal conditions and mentally competent to participate in the study.\n* Not having previous knee surgeries.\n* In condition to complete the study questionnaires.\n\nExclusion Criteria:\n\n* Present some of the contraindications for a treatment with NESA XSIGNAL®: pacemakers, internal bleeding, do not apply electrodes on skin in poor condition, with ulcerations or wounds, acute febrile processes, acute thrombophlebitis and \u002F or electricity phobia.\n* Not having signed the informed consent.\n* Urgent surgical interventions.","16 Years",{"count":77,"type":20},40,[23],"Injury to the anterior cruciate ligament (ACL) is very common among sports professionals and the general population \\[. Unlike other joint injuries, it is reversible, but it can damage adjacent tissues, particularly the meniscus, and catalyze knee osteoarthritis.\n\nACL injury produces instability, joint mechanical alteration, which can lead to degenerative joint diseases. The goal of treating the injury will be to prevent symptomatic instability, restore normal knee kinematics, and prevent degenerative joint disease .\n\nIts usual treatment is surgical and therefore contributes to a significant cost for the health system, both for the surgeries themselves, and for the rehabilitation and subsequent recovery processes.\n\nWithin recovery therapies, in some cases, and given their popularity within the world of physiotherapy, electrotherapy techniques are proposed, primarily transcutaneous electrical nerve stimulation-type techniques with action on the muscular system and analgesia.\n\nAn early intervention with neuromuscular electrostimulation electrotherapy (NMES) combined with repeated exercises is effective for the recovery of strength and restoration of the biomechanical symmetry of the limb.\n\nThere is a diversity of opinions and disparate results regarding the use of this type of technique , in any case, it has been shown that electrical stimulation favors cell migration and joint tissue regeneration.",[81],"Anterior Cruciate Ligament Injuries",[28,29,83],"Anterior Cruciate Ligament",{"date":62,"type":34},{"date":86,"type":34},"2021-05-25",{"date":88,"type":20},"2025-12-25",{"name":40,"class":41},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":42},"100443310","non-invasive-neurostimulation-technology-for-the-treatment-of-type-i-complex-regional-pain-syndrome-crps-i-100443310","NCT05052736","Non Invasive Neurostimulation Technology for the Treatment of Type I Complex Regional Pain Syndrome (CRPS I)","Effectiveness and Safety of NXsignal Applied Surface Neurostimulation Technology for the Treatment of Type I Complex Regional Pain Syndrome (CRPS I)","Inclusion Criteria:\n\n* Meet the Budapest criteria for the clinical diagnosis of CRPS type I.\n* Age between 18 and 65.\n* Period between 0 and 6 months after the onset of the clinical picture.\n* Have signed the informed consent of their own free will.\n\nExclusion Criteria:\n\n* Have a diagnosis of CRPS type II.\n* Present type I CRPS in more than one limb.\n* Patients who have suffered a recurrence of CRPS type I.\n* Pregnancy or plans for it during the study.\n* Previous sympathectomy in the affected limb.",{"count":98,"type":20},42,[23],"Complex Regional Pain Syndrome (CRPS) \u002F Complex Regional Pain Syndrome (CRPS) is a chronic neurological disorder that affects the extremities and is characterized by disabling pain, swelling, vasomotor instability, sudomotor abnormality, and impaired motor function; the duration and clinical magnitude is greater than expected, being divided into three stages of progression over time: Stage I: acute (0-3 months); Stage II: dystrophic (3-9 months); Stage 3: atrophic (9-18 months).\n\nThe purpose of this study is to investigate the effect on complex pain syndrome using a conventional care protocol plus the application of non-invasive neuromodulation during compared to the effect of the same protocol plus placebo.",[102],"Type I Complex Regional Pain Syndrome",[28,29,104],"pain",{"date":62,"type":34},{"date":107,"type":34},"2022-03-28",{"date":109,"type":20},"2026-12-27",{"name":40,"class":41},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":118,"sex":16,"minAge":17,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":21,"phases":122,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100436399","non-invasive-neuromodulation-nesa-through-somatosensory-evoked-potentials-and-sympathetic-cutaneous-responses-100436399","NCT04962737","Non-invasive Neuromodulation NESA Through Somatosensory Evoked Potentials and Sympathetic-cutaneous Responses","Efficacy of Non-invasive Neuromodulation NESA Through Somatosensory Evoked Potentials and Sympathetic-cutaneous Responses in Healthy Subjects","Inclusion Criteria:\n\n* Healthy people\n* Optimal cognitive abilities and mentally competent to participate in the study.\n* In condition to complete the study questionnaires.\n\nExclusion Criteria:\n\n* Focal mononeuropathies in both upper and lower limbs\n* Peripheral neuropathy.\n* Patients with implanted functioning pacemakers \u002F defibrillators. Patients with bleeding disorders. Patients being treated with anticoagulants. Patients on antiplatelet therapy.\n* Present some of the contraindications for a treatment with NESA XSIGNAL®: pacemakers, internal bleeding, do not apply electrodes on skin in bad condition, with ulcerations or wounds, acute febrile processes, acute thrombophlebitis and \u002F or electricity phobia.\n* Not having signed the informed consent.\n* Present any injury or pathology during the study",true,"65 Years",{"count":121,"type":20},15,[23],"Somatosensory evoked potentials are crucial in determining the physiological changes of potentials in nerve pathways. Although their main function is diagnostic, the investigators have recently been used as a physiological test to determine physioelectric changes in healthy subjects to study applied stimuli, such as laser, pain or electrotherapy.",[125],"Healthy Volunteers",[28,29,127,125],"Evoked Potentials","NOT_YET_RECRUITING",{"date":130,"type":34},"2025-08-22",{"date":132,"type":20},"2025-11-28",{"date":134,"type":20},"2026-10-20",{"name":40,"class":41},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":144,"conditions":145,"keywords":150,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":42},"100573530","neutrophil-to-lymphocyte-ratio-and-ca-199-as-predictors-of-perineural-invasion-in-pancreatic-cancer-100573530","NCT06747481","Neutrophil-to-lymphocyte Ratio and CA 19.9 as Predictors of Perineural Invasion in Pancreatic Cancer","Inclusion Criteria:\n\n* Patient with a histopathological diagnosis of adenocarcinoma.\n* Surgical resection of the neoplasm.\n* Preoperative blood count allowing calculation of the neutrophil-to-lymphocyte ratio and preoperative CA 19.9, both before and after neoadjuvant therapy.\n\nExclusion Criteria:\n\n* Patients with a diagnosis of another histological type.\n* Patients with incomplete data.\n* Patients who were not operated on.",{"count":143,"type":20},323,"Pancreatic cancer has an incidence of 1,401,450 new cases diagnosed annually worldwide and is the third leading cause of cancer-related death in Spain. This disease is associated with a poor prognosis, reflected by a 5-year survival rate of less than 5% when all stages are grouped together.\n\nSeveral prognostic factors for pancreatic cancer have been identified. The most relevant include preoperative levels of carbohydrate antigen 19-9 (CA 19.9), surgical margins after resection, venous and\u002For arterial vascular involvement, and histopathological features such as affected locoregional lymph nodes, or perineural and lymphovascular invasion. Among all these factors, perineural invasion may be the primary independent factor affecting prognosis, particularly in patients with relatively favorable pathological features.\n\nThe identification of perineural invasion before surgery could influence the clinical management of these patients. It may facilitate risk stratification, allowing the identification of patients who would benefit most from neoadjuvant treatments or more aggressive surgical procedures, such as vascular resections. However, perineural involvement is very difficult to detect preoperatively.\n\nOnly a few studies have analyzed the possible relationship between CA 19.9 and perineural invasion, and their results are inconsistent. Alternatively, some studies have demonstrated the utility of preoperative multidetector computed tomography in detecting extrapancreatic perineural invasion. However, these radiological tests are still not useful for directly detecting microscopic perineural invasion, especially in early stages.\n\nOn the other hand, in recent years, evidence has supported that the systemic inflammatory response may play an important role in the prognosis of different malignancies. Among these inflammatory markers, the neutrophil-to-lymphocyte ratio (NLR) has gained prominence. Regarding pancreatic cancer, many studies suggest that elevated preoperative NLR levels are associated with a worse prognosis. However, no studies have yet been published analyzing a possible relationship between this inflammatory marker and perineural invasion.\n\nThe main objective of this study is to correlate the neutrophil-to-lymphocyte ratio (NLR) and CA 19.9 with histopathologically confirmed perineural invasion and, in this way, investigate these data as potential preoperative markers of perineural invasion in pancreatic cancer. Our working hypothesis is that preoperative NLR and CA 19.9 are potential markers of perineural invasion.\n\nAs secondary objectives, we aim to study the effect of neoadjuvant therapy on inflammatory markers (NLR) and tumor markers (CEA and CA 19.9) in pancreatic cancer.",[146,147,148,149],"Pancreatic Cancer, Adult","Perineural Invasion","Neutrophil-to-Lymphocyte Ratio","CA 19.9",[151,152,148,149],"pancreatic cancer","perineural invasion","2024-12-20",{"date":155,"type":34},"2024-12-24",{"date":157,"type":34},"2020-01-01",{"date":159,"type":20},"2025-09-30",{"name":40,"class":41},""]